Physicians

Departments / Divisions

• Pediatrics / Pediatrics-Hematology/Oncology
• Pharmacology & Cancer Biology

Address
DUMC 102382
Durham, NC 27710

Appointment Telephone
919-684-3401

Office Telephone
919-684-3401

Fax Telephone
919-681-7950

Training

• MD, Duke University School of Medicine, 1995

Residency

• Pediatrics, Children's Hospital of Philadelphia (Pennsylvania), 1995-1998

Fellowship

• Pediatric Hematology/Oncology, Children's Hospital of Philadelphia (Pennsylvania), 1998-1999
• Pediatric Hematology/Oncology, Duke University Medical Center, 1999-2001

Other Training

• PhD, Cell Biology, Duke University, 1993

Clinical Interests
Pediatric hematology/oncology with emphasis on caring for children, adolescents, and young adults with sarcomas

Research Interests
Pediatric Solid Tumors: Solid tumors are among the most difficult-to-treat cancers in pediatric oncology, with metastatic forms having the highest mortality.  We have established genetically defined human cell-based models for the pediatric skeletal muscle cancer known as rhabdomyosarcoma. Current therapies are based on xenograft models in immunocompromised mice, using established patient-derived patient cell lines, but because of the genetic variability of these cell lines, a true understanding of the causative role of certain genetic changes (e.g. chromosomal translocations) in rhabdomyosarcoma formation is not understood.  Specific goals of this research program include the identification of signaling pathways corrupted in rhabdomyosarcoma, with focus on the PAX3-FOXO1 mutation and its downstream effectors, and identification of new therapeutic targets for treatment of this childhood cancer.

Industry Relationships and Collaborations (What's this?)

This physician has no reported relationships with industry.

Representative Publications
Linardic CM, Counter CM. Genetic modeling of Ras-induced human rhabdomyosarcoma. Methods Enzymol. 2008;438:419-27. (2008) Abstract

Linardic CM. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett. 2008 Oct 18;270(1):10-8. (2008) Abstract

Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res. 2008 Dec 1;68(23):9583-8. (2008) Abstract

Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 2007 Jul 15;67(14):6691-9. (2007) Abstract

Kendall SD, Linardic CM, Adam SJ, Counter CM. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res. 2005 Nov 1;65(21):9824-8. (2005) Abstract

Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM. Genetic modeling of human rhabdomyosarcoma. Cancer Res. 2005 Jun 1;65(11):4490-5. (2005) Abstract